CCL23

Across TCGA pan-cancer cohorts, CCL23 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CCL23 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher CCL23 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCL23 expression acts as an unfavorable survival marker.

THCA and BRCA are the cancer types where CCL23 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.027	0.945	<.001	24	view →
BRCA	OS	Median	All	0.112	0.578	.012	18	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CCL23–THCA (DFS)

Open the THCA breakdown →